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ABSTRACT 
Objective: Regorafenib demonstrated efficacy in metastatic colorectal cancer 
(mCRC) patients. Lack of predictive biomarkers, potential toxicities and cost 
effectiveness concerns highlight the unmet need for better patient selection.  
Design: RAS mutant mCRC patients with biopsiable metastases were enrolled in 
this phase II trial. Dynamic contrast enhanced (DCE) MRI was acquired pre and at 
day 15 post-treatment. Median values of volume transfer constant (Ktrans), enhancing 
fraction (EF) and their product KEF (summarised median values of Ktrans x EF) were 
generated. Circulating tumour (ct) DNA was collected monthly until progressive 
disease and tested for clonal RAS mutations by digital-droplet PCR. Tumour 
vasculature (CD-31) was scored by immunohistochemistry on 70 sequential tissue 
biopsies.  
Results: Twenty seven patients with paired DCE-MRI scans were analysed. Median 
KEF decrease was 58.2%. Of the 23 patients with outcome data, >70% drop in KEF 
(6/23) was associated with higher disease control rate (p=0.048) measured by 
RECIST v1.1 at 2 months, improved progression free survival (PFS) [Hazard ratio 
(HR) 0.16 (95% CI 0.04-0.72), p=0.02], 4-month PFS (66.7% vs. 23.5%) and overall 
survival (OS) [HR 0.08 (95% CI 0.01-0.63), p=0.02]. KEF drop correlated with CD-31 
reduction in sequential tissue biopsies (p=0.04). RAS mutant clones decay in ctDNA 
after 8 weeks of treatment was associated with better PFS [HR 0.21 (95% CI 0.06 - 
0.71), p=0.01] and OS [HR 0.28 (95% confidence interval 0.07 - 1.04), p=0.06].  
Conclusions: Combining DCE-MRI and ctDNA predicts duration of anti-angiogenic 
response to regorafenib and may improve patient management with potential 
health/economic implications.  
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Significance of the Study 
What is already known on this subject? 
• Regorafenib is approved as third-line therapy for patients with refractory CRC; 
however, its use in the clinic has been restricted due to modest clinical benefit 
in unselected patients.  
• Published pre-clinical studies suggested that anti-angiogenic activity of 
regorafenib is the main pre-determinant of its efficacy but no clinical studies 
have validated these findings. 
• Retrospective analysis of prospective clinical trials failed to identify 
biomarkers od response to regorafenib that might be implemented in clinical 
practice. 
 
What are the new findings? 
• Regorafenib showed significant activity in patients with marked early anti-
angiogenic response, resulting in a longer disease control, better PFS and 
OS.  
• Early (day 15 post-treatment) DCE-MRI predicts response and long term 
outcome during Regorafenib treatment.  
• Sequential analysis of tissue biopsies confirmed that reduction in tumour 
vasculature as the mechanism underpinning the observed radiological 
findings.  
• Persistent regorafenib-induced anti-angiogenic effect translates into a 
reduction in circulating tumour (ct) DNA and this might be incorporated into 
the clinical algorithm for patients’ management.   
 
Implications on clinical practice 
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Implementing the use of DCE-MRI and ctDNA analysis as early biomarkers of 
response to regorafenib might improve patient selection with clear health/economic 
implications for patients, health systems and society. 
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Introduction 
Colorectal cancer (CRC) remains a major health burden with significant morbidity 
and mortality despite recent improvements in its management owing to better 
screening and therapeutic options[1]. CRC is known to be a biologically 
heterogeneous disease characterised by the activation of several angiogenic and 
oncogenic pathways[2]. Regorafenib, a multikinase inhibitor (MKI) with known anti-
angiogenic, anti-stromal and anti-oncogenic activities[3], has demonstrated single 
agent efficacy in patients with treatment refractory metastatic CRC (mCRC)[4, 5]. 
The use of regorafenib in the clinic is however hampered by the modest efficacy in 
an unselected patient population, a significant side effect profile and the high drug 
costs. Consequently, identification of predictive biomarkers of response and 
resistance to regorafenib is critical for treatment stratification and appropriate patient 
selection such that treatment benefits could be optimised. 
Several efforts are currently ongoing to define gene signatures [6] and bio-markers of 
response to anti-angiogenic drug in CRC and other cancers[7]; however, ongoing 
validation will only determine the use of these biomarkers in clinical practice. Whilst 
recent studies utilising tissue [8] and plasma [9, 10] have attempted to elucidate the 
response and resistance mechanisms to regorafenib, the search for a clinically useful 
biomarker has been largely unsuccessful. A growing body of pre-clinical evidence 
suggests strong anti-angiogenic and pro-apoptotic effects of regorafenib [11, 12, 13, 
14] with clinical data demonstrating that drug activity is independent of the tumour’s 
mutational status[8]. These findings strengthen the hypothesis that additional 
mechanisms other than oncogenic blockade are responsible for the anti-tumour 
activity of this drug. Dynamic contrast enhanced magnetic resonance imaging (DCE-
MRI) may have a useful role in evaluating tumour vascular heterogeneity and early 
anti-angiogenic effects[15],[16]; moreover, its parameters volume transfer constant 
(Ktrans), enhancing fraction (EF), and initial area under the gadolinium concentration-
time curve over 60 seconds (IAUGC60) have been correlated with micro-vessel 
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density and in some tumours with degree of VEGF expression [17]. By contrast, 
diffusion weighted MRI (DW-MRI) offers useful information that reflects tumour 
cellularity and increase in its quantitative parameter Apparent Diffusion Coefficient 
(ADC) has been associated with tumour cell death and necrosis[18, 19]. At least two 
pre-clinical studies demonstrated that regorafenib was able to significantly suppress 
tumour vascularity when quantified by DCE computed tomography (CT) and MRI 
modalities respectively in human colon carcinoma xenograft models[14, 20].  
In this prospective phase II trial of patients with RAS mutant mCRC treated with 
single agent regorafenib we hypothesised that 1) an early anti-angiogenic and anti-
proliferative activity of regorafenib might be detected by multi-parametric DCE-MRI 
on day 15 of the treatment 2) the depth of anti-angiogenic response detected by a 
significant drop in DCE-MRI quantitative parameters might correlate with clinical 
efficacy 3) analysis of sequential tissue and liquid biopsies could be integrated into 
the biomarker discovery process and shed insights into mechanisms of response to 
regorafenib. 
 
Material and Methods  
Clinical Trial Design 
PROSPECT-R trial (clinical trials.gov number [NCT03010722],) is a phase II, open 
label, non-randomised study of regorafenib in patients with RAS mutant, chemo-
refractory mCRC (Fig. 1). Patients who were at least 18 years old and had a World 
Health Organisation (WHO) performance status (PS) of 0-1, were deemed eligible if: 
all conventional treatment options including fluorouracil, irinotecan, oxaliplatin and at 
least one anti-VEGF drugs (later trial protocol was amended due to changes in 
availability of anti-VEGF agents due to funding restrictions in UK) were exhausted; 
they had metastatic tumour amenable to biopsy and repeat measurements with DCE-
MRI. Written informed consent was obtained from all patients. The study was carried 
out in accordance with the Declaration of Helsinki and approved by National 
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Institutional review boards [Medicines and Healthcare products Regulatory Agency: 
15983/0249/001-0001]. All participants were required to have mandatory pre-
treatment biopsies (6 cores targeted towards the MRI identified index lesion), 
biopsies at 2 months [if response or stable disease by RECIST v1.1 criteria (6 cores)] 
and at the time of progression (6-12 cores from two suitable progressing metastatic 
sites). 3 out of 6 cores were snap-frozen; one core was used to establish patient- 
derived organoids and two cores were formalin fixed and paraffin embedded (FFPE). 
The results section describes the number of cores used for immunohistochemistry 
analysis in the current study. Further genomic, transcriptomic and functional analyses 
are on-going on the remaining cores. Patients with suitable metastatic disease 
(defined as lesions at least 2 cm in diameter) and no contraindications to MRI 
underwent multiparametric MRI studies including matched DCE and DWI; images 
were acquired less than 7 days prior to therapy and at day 15 post-treatment. 
Treatment consisted of regorafenib 160mg once daily on a schedule of three weeks 
on and one week off until progression or intolerable side effects. More details on 
inclusion and exclusion criteria and criteria for patients’ withdrawal on the study are 
provided in the online supplementary material. 
 
MRI data processing: 
DCE-MRI data were post-processed using the Magnetic Resonance Imaging 
Workbench software developed at our institution [21]. The pharmacokinetic analysis 
was based on the extended Kety/Tofts model in conjunction with a cosine-based 
arterial input function (AIF) model derived from population-averaged values[22, 23]. 
DCE-MRI parameters including Ktrans, IAUGC60 and the EF were obtained for 
pre/post-treatment datasets. Ktrans estimates were reported for both whole tumour 
[Ktrans(all)] and valid voxels only [Ktrans(nonzeros), i.e. excluding all non-enhancements 
and non model-fits] in order to address the extended necrosis observed in the cohort. 
The EF was defined as percentage of the voxels that enhance above the noise floor 
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out of all tumour voxels. A voxel was considered enhancing when it’s post-contrast 
(Dotarem, Guerbet, France) dynamic intensity signal was at least one standard 
deviation higher than the mean pre-contrast signal, for a period of 60s post contrast 
onset.  Finally, volume change in tumour enhancement during therapy (such as new 
necrosis) was accounted for by reporting a composite parameter, KEF, which is the 
product of summarised median values of KEF= Ktrans (nonzeros) x EF[24]. For KEF, 
an ROC curve analysis was performed to establish the cut off able to identify 
meaningful clinical benefit based on disease control rate (DCR), progression free 
survival (PFS) and overall survival (OS).  
 
Digital Droplet (dd) PCR  
The QX200 ddPCR system (Bio-Rad, Berkeley, California) was used and all 
reactions were prepared using the ddPCR Supermix with no dUTTP for Probes. All 
PCR reactions were performed as duplex PCR using the relevant digital PCR assays 
for the wild-type and the mutation in question. Droplets were generated using the 
QX200 droplet generator according to the manufacturer’s protocols. The PCR 
reaction was performed in a C1000 Touch Thermo Cycler (Bio-Rad) using the 
following protocol: 95°C for 10 min followed by 40 cycles of 94°C for 30 sec and 55°C 
for 1 min, then 98°C for 10 min. Droplets were read in the QX200 droplet reader and 
analyzed using the Quantasoft software version 1.6.6.0320 (Bio-Rad). Fractional 
Abundance (FA) was defined as follows: F.A. % = (Nmut/(Nmut + Nwt)) × 100), 
where Nmut is the number of mutant events and Nwt is the number of WT events per 
reaction. The number of positive and negative droplets was used to calculate the 
concentration of the target and reference DNA sequences and their Poisson-based 
95% confidence intervals. ddPCR analysis of normal control plasma DNA (from cell 
lines) and no DNA template controls were always included. Samples with very low 
positive events were repeated at least twice in independent experiments to validate 
the obtained results as previously described[25]. 
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CD31, Ki-67 and Caspase-3 immunohistochemical staining 
The immunohistochemical expression of microvascular density (CD31; clone 
ab28364, Abcam, Cambridge, UK; dilution 1:50), cell proliferation (Ki-67; clone 
ab16667, Abcam; dilution 1:100), and cell apoptosis (Cleaved Caspase-3 (Asp175) 
(5A1E) ab9664S, Abcam; dilution 1:100) was examined on consecutive 4-µm 
formalin-fixed and paraffin-embedded (FFPE) sections of the neoplastic cores. 
Reactions were performed using the automated Benchmark® XT platform (Ventana 
Medical Systems, Basel, Switzerland). Appropriate positive and negative controls 
were run concurrently. 
For assessment of tumour microvascular density, CD31-positive micro-vessels were 
quantified and reported as the average number in 10 random fields at 200x 
magnification. Ki-67 labelling index was assessed as the average number of 
proliferating cells in 10 random fields at 200x magnification. Caspase-3 evaluation 
was categorized as positive or negative.  
Statistical Analysis  
The Disease Control Rate (DCR) was defined by the sum of complete responses 
(CR) + partial responses (PR) + stable diseases (SD) using RECIST v1.1. PFS was 
measured from start of treatment to date of progression or death from any cause. OS 
was defined as time from start of treatment to death of any cause. Patients without 
an event were censored at last follow up. Response according to KEF (Ktrans 
(nonzeros) x EF) was defined as a drop of >70% from baseline whilst change in 
CD31 biomarker levels from baseline was calculated as [(8wks-baseline)/ baseline] 
*100. CD31 change from baseline was explored on a continuous scale and was also 
dichotomised using the median value. 
Response according to KEF parameter and the dichotomised CD31 change from 
baseline were cross-tabulated with the RECIST measured DCR. Chi2 or Fisher’s 
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exact tests were employed to explore whether there is an association between them 
and DCR. Logistic regression was employed to produce odds ratios (ORs) and 95% 
confidence intervals (CIs). The PFS and OS rates were estimated using the Kaplan-
Meier method and survival curves were generated for each group. The log-rank test 
was used to compare the survival curves and a Cox proportional hazards model was 
fitted to obtain hazard ratios (HRs) and 95% CIs. The proportional hazards 
assumption was tested with the use of Schoenfeld residuals. 
In our study, despite relatively small study cohort, the changes in Ktrans and KEF 
values were noticeably larger (e.g. > 50% reduction in mean and median KEF). 
Based on results of the 23 analysable patients evaluated by DCE-MRI in our study, 
our patient sample size by post-hoc analysis (based on Wilcoxon-signed rank test) 
demonstrated 100% power to detect this difference at a level of significance of 0.05. 
 
Additional Methods can be found in the Online Appendix  
 
Results 
Patients’ characteristics and tissue collection 
Twenty seven treated patients (63% males) were recruited in the DCE-MRI 
PROSPECT-R trial and a total of 143 cores were collected by tissue biopsies from 70 
metastatic lesions for the current analysis. Right and left sided primary cancers were 
equally distributed in the study population; other relevant patient characteristics are 
summarised in Table 1.  
Fifty-four tissue cores were obtained from BL biopsies of 27 treated (27 lesions) 
patients; of the 14 patients with SD at 8 weeks, 24 tissue cores were obtained from 
12 (12 lesions) patients (one patient missed the biopsy due to a hospital admission 
secondary to chest infection and the other developed treatment related rectal wall 
perforation). A further 65 tissue cores were obtained from 23 evaluable patients (35 
lesions in total; 12 patients with two progressing lesions each) with PD (3 patients did 
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not complete 2 cycles of treatment and 1 came off due to treatment related rectal wall 
perforation). There was 89% concordance between target DCE-MRI and biopsied 
metastatic lesions (Appendix Table A1). Two FFPE cores per patient were tested at 
each time-point. One-hundred and nine plasma samples were tested to track RAS 
mutant clones in 21 corresponding patients; patients were required to have at least 
one sample available at 2 months following treatment.  
 
Radiological and pathological evidence of early regorafenib induced anti-
angiogenic effects 
A significant drop in all DCE-MRI parameters was seen after 2 weeks of treatment; 
median Ktrans, IAUGC60, EF and KEF product
 decreased by 27.8% [interquartile range 
(IQR) 6.7-52.6], 57.7% (32.7-67.9), 35.3% (12.4-56.2) and 58.3% (28.3-76.1) 
(Appendix Table A2). The ROC curve analysis performed for the KEF showed that a 
69.21% reduction from baseline had 100% specificity and overall accuracy of 
69.57%; for pragmatic reasons a minimum KEF product reduction of 70% was 
chosen (Appendix Table A3). Matched tissue analysis revealed a strong 
concordance between a drop in KEF and mean vascular density of tissue, as 
measured by CD31 count obtained pre-treatment and at 8 weeks in patients with 
tissue and MR parameter data available (p=0.04). (Appendix Table A4).   
 
Correlation of functional imaging data and CD31 staining with clinical 
parameters 
After a median follow up of 14.3 months [(95% CI 4.9 – not evaluable (NE)], IQR 4.9- 
not reached (NR)], 23 patients, who had at least 1 cycle of regorafenib and a 
response assessment by computed tomography (CT) scan at 2 months were 
analysable. DCR at 2 months, median PFS and median OS were 51.9%, 3.6 months 
(95% CI 1.9-4.2 months) and 5.8 months (95% CI 4.7-13.3 months) respectively; 
77.4% (95% CI 54.0-89.9%), 48.0% (95% CI 24.1-68.5%) and 32.0% (95% CI 11.2-
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53.4%) of patients were alive at 4, 6 and 12 months respectively. Patients with >70% 
drop in KEF (8/27; 2 patients didn’t undergo the 2 month scan due to treatment-
related toxicities and thus were excluded from the final analysis as per the study 
protocol) were found to have higher DCR (6/6 vs. 0/6, p=0.05) at 2 months (Appendix 
Table A5), better PFS [HR 0.16 (95% CI 0.04-0.72), p=0.02], better PFS at 4-months 
(66.7% vs. 23.5%) and better OS [HR 0.08 (95% CI 0.01-0.63), p=0.02]. For the 
group with >70% drop in KEF, 6-month and 12-month OS were 100% (95% CI NE) 
and 75% (95% CI 12.8% - 96.1%) respectively compared to 27.6% (7.2-53.2%) and 
13.8% (1.0-42.5%) in the <70% drop in KEF group (Fig 2A-B; Appendix Figure A1 
and Appendix Table A6). In order to address the relative improvement in efficacy with 
or without KEF drop, we compared the outcomes of all the patients who achieved 
DCR; PFS was found to be 5.6 vs. 4.2 months [HR 0.30 (95% CI 0.06-1.49), 
p=0.140) and OS was 15.2 vs. 5.8 months [HR 0.11 (95% CI 0.01-1.06), p=0.057] in 
this analysis. Interestingly, when the same analysis was repeated with the cut-off 
chosen by ROC analysis (69.21%), PFS [HR 0.18 (95% CI 0.03-0.91), p=0.038] and 
OS [HR 0.11 (95% CI 0.01-1.01), p=0.051] were found to be statistically significant 
despite small numbers.   
A decrease in CD31 score at 2 months was associated with higher DCR [OR 30.0 
(95% CI 2.22- 405.98), p=0.01], better PFS [HR 0.13 (95% CI 0.03- 0.52), p=0.004] 
and better OS [HR 0.30 (95% CI 0.08- 1.06), p=0.06] (Appendix Fig. A2). Examples 
of KEF drop, RECIST 1.1 response and CD31 scoring at different time-points in a 
responder (Fig. 3A-C) and non-responder patient (Fig. 3D-F) are provided.  
 
Radiological and pathological analysis of proliferation and apoptosis following 
regorafenib treatment 
Radiological cell kill effects of regorafenib were investigated by examining the 
changes in ADC on DW-MRI, pre-treatment and at day 15. Matching tissue was 
scored for cell proliferation (KI-67 index) and apoptosis (caspase 3) at pre-treatment 
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and 2 months post therapy. Median ADC changes are described in Appendix Table 
A7. The changes at 2 months in corresponding tissue parameters of cell proliferation 
was not associated with an improvement in DCR [OR 1.13 (95% CI 0.14-9.0), 
p=0.91], PFS [HR 1.11 (95% CI 0.35- 3.58), p=0.86] or OS [HR 0.91 (95% CI 0.19-
4.42), p=0.91], similarly no significant changes in apoptosis were observed when 
comparing baseline and 2 months treatment tissue biopsies. 
 
Liquid biopsy as a surrogate marker of response to regorafenib  
We hypothesised that regorafenib-induced anti-angiogenic effects would correlate 
with a reduction in ctDNA. Indeed, in a patient with significant (71%) KEF drop after 2 
weeks of treatment (Fig. 4A) and durable RECIST v1.1. response lasting nearly 12 
months (Fig. 4B-D), we observed that not only did the KEF reduction correlated with 
CD31 drop (Fig. 4E) but was also associated with a rapid and marked decrease in 
KRAS G12D ctDNA which persisted for the entire duration of the treatment and 
increased again when the treatment was halted due to a complication (Fig. 4F).  
Intriguingly, the changes in CEA lagged behind the changes in ctDNA. 
To test this hypothesis we analysed changes in RAS mutant clones in sequential 
liquid biopsies by ddPCR. We examined whether a drop in fractional abundance (FA) 
was associated with clinical efficacy parameters. We found that the loss of detectable 
mutant RAS clones in ctDNA after 4 weeks was universal to all the examined 
patients [(n=21) data not shown]. However, a sustained drop in ctDNA was observed 
in 47.6% of the patients at 2 months and was associated with better median PFS [HR 
0.21 (95% CI 0.06 - 0.71), p=0.01] and OS [HR 0.28 (95% CI O.07-1.04), p=0.06] 
respectively (Fig. 5A and 5B); PFS was 60.0% (after 4 months) and 40.0% (after 6 
months) in the groups with decrease in FA. In a multivariate analysis adjusting for 
KEF reduction, this effect was associated with better PFS [HR 0.23 (95% CI 0.07-
0.75), p=0.02]. 
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Despite the small numbers, which precluded any statistical analysis, it was 
remarkable to observe that patients with a KEF drop >70% and decrease in ctDNA 
FA had the most durable response to regorafenib (Fig. 5C) 
 
Known biomarkers of benefit from Regorafenib, toxicity profile and clinical 
outcome in the PROSPECT-R trial. 
A previously well conducted study comprising of 208 regorafenib treated patients 
demonstrated an association between high neutrophil, high platelet, low lymphocyte 
count and/or high neutrophil lymphocyte ration (NLR) with prognosis [26]. Due to the 
stringent inclusion criteria of our study, our data distribution did not allow to use the 
same cut of used in the study be Del Prete and colleagues and median values were 
used instead. Notwithstanding small numbers and patient selection based on trial 
inclusion/exclusion criteria, no significant correlation with efficacy was found with any 
of the above-mentioned factors (Appendix Tables A8 and A9). 
Moreover, other clinical factors such as performance status, and number of 
previously lines of treatment and toxicity were also compared against efficacy in a 
univariate analysis. Treatment related adverse events were consistent with 
previously reported data [4] and are summarised in Appendix Tables A10 and A11. 
As expected, patients who required >50% dose reduction and received less than 2 
cycles of regorafenib derived less benefit from the treatment (Appendix Tables A12).  
 
Discussion 
This proof of concept phase II translational research study was designed to assess 
the feasibility of combining imaging, morphological and plasma biomarkers in order to 
best stratify patients more likely to derive benefit from regorafenib in refractory 
mCRC. Our study provides the first clinical evidence that regorafenib efficacy is 
driven by its early anti-angiogenic activity. 
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It is widely accepted that DCE-MRI can assess tumour vascular function[27]; 
however, establishing common methodology remains challenging due to the 
practicalities of technical implementation across different MR platforms and the 
choice of mathematical models for data analysis. In this study, we have used DCE-
MRI acquisition and data analysis in line with international expert recommendations 
[27]. Whilst a large body of evidence supports the notion that perfusion MRI can be 
helpful in assisting dose selection and enriching patient populations more likely to 
respond in early phase clinical trials, most studies have defined an observable anti-
angiogenic drug effect based only on the limits of DCE-MRI measurement 
repeatability rather than also considering the clinical efficacy[28]. Furthermore, as 
metastases show variable degrees of necrosis and non-enhancement before 
treatment and drug induced vascular pruning also leads to marked decrease in 
enhancement within tumors, measuring only the median Ktrans value is less sensitive 
to change due to averaging of the voxel values.  For these reasons, we calculated 
the EF and the product of Ktrans from the enhancing voxels with EF (KEF), which 
better reflects proportional reduction of vascularity within tumours[24]. 
 
In this study, we have evaluated DCE-MRI in a well-defined study population, thus 
minimizing the bias that may result from patient heterogeneity. The selected DCE-
MRI parameter threshold applied for patient stratification is based on both a prior 
knowledge of the measurement repeatability of our technique [29] as well as clinically 
validated endpoints of PFS and OS. To our knowledge, this is the first prospective 
study showing that KEF, a product of Ktrans and EF, can be used as a parameter of 
DCE-MRI with high clinical specificity. The KEF measurement was able to identify 
clinically meaningful responders as early as 2 weeks into treatment with regorafenib 
with 100% specificity.  
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The major strength of this study are that it was possible to validate the findings of 
MRI detected regorafenib-induced suppression of tumour vascularisation by matched 
tissue analysis using immunostaining of the endothelial marker CD31. We 
demonstrated that patients with a significant drop in CD31 score on 2-month biopsy 
had a better PFS and OS. These findings further emphasise the fact that drug activity 
is due to its anti-proliferative properties.  
 
It is established that genetic and non-genetic mechanisms of tumour heterogeneity 
allow functional expansion of previously dormant subclones under the selective 
pressure of chemotherapy in CRC cells [30]. This provides a strong biological 
rationale for the use of regorafenib given its broad multi-kinase anti-tumour activity. 
However, the diversity of mechanisms of action of this drug makes it equally 
challenging to identify predictive biomarkers of clinical utility. Biomarker analysis of 
CORRECT trial data demonstrated that benefit from regorafenib was independent of 
the RAS pathway mutational status of the tumour, suggesting primarily an 
antiangiogenic mechanism of action, and that liquid biopsy could be reliably used to 
characterize clonal mutations[8]. We investigated if the circulating tumour genotype 
could be used as a biomarker of sustained anti-angiogenic activity to regorafenib by 
tracking known KRAS clonal mutations and performing serial plasma analysis by 
highly sensitive ddPCR methodology, at clinically relevant time points. A drop in FA 
was observed in all patients at 4 weeks suggesting a degree of initial anti-angiogenic 
activity in keeping with an initial drop in radiological parameters; however, this effect 
was sustained in only a proportion of patients at 2 months. This group of patients with 
persistent drop at 2 months demonstrated better efficacy with regorafenib suggesting 
that sustained angiogenic activity was required in order to achieve maintained benefit 
from therapy. Consistent with the findings from previous studies [25, 31], we 
demonstrated that ctDNA can be used for tumour genotyping, but beyond this we 
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proved that it can also be used to monitor efficacy from regorafenib in patients 
showing initial benefit from the therapy.  
 
Acknowledging the limitations due to small numbers of patients in our study, we 
propose that these findings should be validated in larger cohort of patients treated 
with anti-angiogenic therapies. Due to logistical barriers, it may however not be 
possible to conduct large scale trials scrupulously designed and statistically powered 
to address questions of biomarker analysis. The interpretation of our findings thus 
need to be contextualized; for example, regorafenib is currently unavailable free of 
charge to patients in the United Kingdom so the use of biomarkers described in this 
study could significantly reduce the duration of therapy in patients’ unlikely to derive 
benefit. It is conceivable that the health economic assessment might be more 
favorable with appropriate predictive biomarkers such as those we have identified.  
Whilst, the search for a positive predictive biomarker may help better application of 
precision medicine, in a more non-resource-constrained funding environment, based 
on our findings, patients could be spared from significant drug-related side effects, 
which again would have health-economic benefits.  
 
In summary, the depth of angiogenic response measured by DCE-MRI and validated 
by matched tissue IHC analysis correlates with clinical efficacy. The circulating 
tumour genotype is a potential marker of sustained anti-angiogenic response to 
regorafenib in patients with known clonal mutations.  
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Table 1: Baseline characteristics of participating patients 
 
 No. % 
   
Age, median [range] 63.7 [36.3-79.0] 
   
Gender   
Female 10 37 
Male 17 63 
   
Site of primary   
Rectal 7 26 
Left Colon 9 33 
Right Colon 11 41 
   
Histology Diagnosis   
Unknown 1 4 
Adeno (mucinous) 4 15 
Adeno (non-mucinous) 22 81 
   
Stage Diagnosis   
Stage II 5 19 
Stage III 5 19 
Stage IV 17 62 
   
Radiotherapy to 
primary 
  
Yes 4 15 
No 23 85 
   
Number of lines in 
metastatic setting 
  
1 1 4 
2 11 41 
3 9 33 
4 3 11 
5 2 7 
6 1 4 
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Figure Legends 
Figure 1: PROSPECT-R Trial design. Patients meeting all inclusion and no 
exclusion criteria were required to have pre-treatment CT, DCE-MRI, and DW-MRI 
scans; MRI scans were then repeated on day 15. All patient were also required to 
have pre-treatment mandatory core biopsy, followed by a core biopsy at 2-months if 
they had SD or PR. Patients were monitored  by CT scans every 2 months until the 
time of PD and if clinically feasible, they had biopsy of 1 or 2 progressing lesions 
from PD sites. Plasma samples were collected every 4 weeks until the time of PD. 
CT=computed tomography; ctDNA= circulating tumour DNA; DCE=dynamic contrast 
enhanced; DW= diffusion weighted; MRI=magnetic resonance imaging; 
PD=progressive disease; PR=partial response; SD= stable disease. 
 
Figure 2: Outcome according to radiological parameters in the PROSPECT-R 
Trial. Kaplan-Meier curves for progression-free survival (A) and overall survival (B) in 
patients with or without KEF drop.  
 
Figure 3: Correlation between radiological and pathological findings in the 
PROSPECT-R Trial. Panels A-C demonstrate an example of a patient with durable 
disease control of 14 months, whilst panel D-F shows example of a primary 
resistance patient (2 months). (A) Coronal DCE-MRI (central slice of a liver lesion) 
showing significant reduction in the median Ktrans [min-1] with accompanying 
histogram (whole lesion) at day 15 post-treatment. (B) Coronal CT images at 
baseline, best response (2 months) and at the end of treatment (14 months) for same 
liver lesion (left) and an abdo-pelvic mass (right). Patient achieved SD by RECIST 
v1.1. (C) Matched IHC analysis demonstrating decrease and subsequent increase in 
tumour vascularity measured by staining CD31 at 2 months and 14 months 
respectively. (D) Coronal DCE-MRI and accompanying histogram of the liver lesion 
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showing no significant reduction in the median Ktrans [min-1] at day 15 post treatment. 
(E) Coronal CT images of the liver showing progression (30% increase) of the same 
target liver lesion (yellow circle) at baseline and at progression (2 month scan). (F) 
Matched IHC analysis demonstrating no change in tumour vascularity measured by 
staining CD31 at 2 months. Two separate PD lesions were analysed to take into 
account tumour heterogeneity; however, no change in vascularity was observed in 
either of the biopsied lesion. 
CT=computed tomography; DCE=dynamic contrast enhanced; IHC-
immunohistochemistry; MRI=magnetic resonance imaging; PD=progressive disease; 
SD= stable disease. 
Figure 4: Correlation between radiological, pathological and circulating 
biomarkers in PROSPECT-R Trial. (A) Axial DCE-MRI demonstrating significant 
reduction (71%) of the median Ktrans[min -1] in the left pelvic wall recurrence, with 
accompanying histogram at day 15 post-regorafenib. (B) Three dimensional 
representation of target lesion by CT performed at baseline and at week 31 (best 
response), demonstrating reduction in lesion volume. (C) FDG-PET images 
performed at 4 months of therapy, showing residual FDG uptake, although 
significantly less when compared to a historic PET-CT performed 18 months prior to 
regorafenib therapy. (D) Axial CT images demonstrating a maintained RECIST V1.1 
PR (45%) to regorafenib for 31 weeks. Images show representative sites of disease 
including: left pelvis side wall, mediastinal lymphadenopathy, and large lung 
metastases (yellow circles). Note is made that at the time of progression, left pelvic 
side wall disease progressed (28%), while the remaining disease had maintained 
partial response demonstrating the inter-tumoural heterogeneity in resistance to 
regorafenib. (E) Matched IHC analysis demonstrating decrease and subsequent 
increase in tumour vascularity measured by staining CD31 at 2 months and 12 
months respectively. (F) Graphical representation of clonal KRAS mutation tracked 
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by ddPCR analysis of ctDNA analysis compared with CEA and total volume of target 
lesions measured RECIST v1.1 assessment. This demonstrates that an early drop 
and rise in fractional abundance (FA) of KRAS mutation that precedes changes in 
CEA, both at response and resistance to regorafenib  
CEA=Carcino-Embryonic Antigen; ctDNA=circulating tumour; CT=computed 
tomography; DCE=dynamic contrast enhanced; ddPCR=digital droplet polymerase 
chain reaction; FA=fractional abundance; FDG-PET=18-Fluoro-deoxyglucose 
positron emission tomography; IHC=immunohistochemistry; MRI=magnetic 
resonance imaging; PD=progressive disease; PR=partial response 
Figure 5: Outcome according to ctDNA drop after 2 months of treatment in the 
PROPSECT-R Trial. Kaplan-Meier curves for progression-free survival (A) and 
overall survival (B) in patients with or without ctDNA drop, (C) spider plot 
demonstrating depth and duration of response to regorafenib (evaluated by RECIST 
v1.1. criteria) according to KEF and ctDNA drop. 
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Figure 1: PROSPECT-R Trial design. Patients meeting all inclusion and no exclusion criteria were required to 
have pre-treatment CT, DCE-MRI, and DW-MRI scans; MRI scans were then repeated on day 15. All patient 
were also required to have pre-treatment mandatory core biopsy, followed by a core biopsy at 2-months if 
they had SD or PR. Patients were monitored  by CT scans every 2 months until the time of PD and if 
clinically feasible, they had biopsy of 1 or 2 progressing lesions from PD sites. Plasma samples were 
collected every 4 weeks until the time of PD. CT=computed tomography; ctDNA= circulating tumour DNA; 
DCE=dynamic contrast enhanced; DW= diffusion weighted; MRI=magnetic resonance imaging; 
PD=progressive disease; PR=partial response; SD= stable disease.  
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Figure 2: Outcome according to radiological parameters in the PROSPECT-R Trial. Kaplan-Meier curves for 
progression-free survival (A) and overall survival (B) in patients with or without KEF drop.  
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Figure 3: Correlation between radiological and pathological findings in the PROSPECT-R Trial. Panels A-C 
demonstrate an example of a patient with durable disease control of 14 months, whilst panel D-F shows 
example of a primary resistance patient (2 months). (A) Coronal DCE-MRI (central slice of a liver lesion) 
showing significant reduction in the median Ktrans [min-1] with accompanying histogram (whole lesion) at 
day 15 post-treatment. (B) Coronal CT images at baseline, best response (2 months) and at the end of 
treatment (14 months) for same liver lesion (left) and an abdo-pelvic mass (right). Patient achieved SD by 
RECIST v1.1. (C) Matched IHC analysis demonstrating decrease and subsequent increase in tumour 
vascularity measured by staining CD31 at 2 months and 14 months respectively. (D) Coronal DCE-MRI and 
accompanying histogram of the liver lesion showing no significant reduction in the median Ktrans [min-1] at 
day 15 post treatment. (E) Coronal CT images of the liver showing progression (30% increase) of the same 
target liver lesion (yellow circle) at baseline and at progression (2 month scan). (F) Matched IHC analysis 
demonstrating no change in tumour vascularity measured by staining CD31 at 2 months. Two separate PD 
lesions were analysed to take into account tumour heterogeneity; however, no change in vascularity was 
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observed in either of the biopsied lesion.  
CT=computed tomography; DCE=dynamic contrast enhanced; IHC-immunohistochemistry; MRI=magnetic 
resonance imaging; PD=progressive disease; SD= stable disease.  
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Figure 4: Correlation between radiological, pathological and circulating biomarkers in PROSPECT-R Trial. (A) 
Axial DCE-MRI demonstrating significant reduction (71%) of the median Ktrans[min -1] in the left pelvic wall 
recurrence, with accompanying histogram at day 15 post-regorafenib. (B) Three dimensional representation 
of target lesion by CT performed at baseline and at week 31 (best response), demonstrating reduction in 
lesion volume. (C) FDG-PET images performed at 4 months of therapy, showing residual FDG uptake, 
although significantly less when compared to a historic PET-CT performed 18 months prior to regorafenib 
therapy. (D) Axial CT images demonstrating a maintained RECIST V1.1 PR (45%) to regorafenib for 31 
weeks. Images show representative sites of disease including: left pelvis side wall, mediastinal 
lymphadenopathy, and large lung metastases (yellow circles). Note is made that at the time of progression, 
left pelvic side wall disease progressed (28%), while the remaining disease had maintained partial response 
demonstrating the inter-tumoural heterogeneity in resistance to regorafenib. (E) Matched IHC analysis 
demonstrating decrease and subsequent increase in tumour vascularity measured by staining CD31 at 2 
months and 12 months respectively. (F) Graphical representation of clonal KRAS mutation tracked by ddPCR 
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analysis of ctDNA analysis compared with CEA and total volume of target lesions measured RECIST v1.1 
assessment. This demonstrates that an early drop and rise in fractional abundance (FA) of KRAS mutation 
that precedes changes in CEA, both at response and resistance to regorafenib  
CEA=Carcino-Embryonic Antigen; ctDNA=circulating tumour; CT=computed tomography; DCE=dynamic 
contrast enhanced; ddPCR=digital droplet polymerase chain reaction; FA=fractional abundance; FDG-
PET=18-Fluoro-deoxyglucose positron emission tomography; IHC=immunohistochemistry; MRI=magnetic 
resonance imaging; PD=progressive disease; PR=partial response  
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Figure 5: Outcome according to ctDNA drop after 2 months of treatment in the PROPSECT-R Trial. Kaplan-
Meier curves for progression-free survival (A) and overall survival (B) in patients with or without ctDNA 
drop, (C) spider plot demonstrating depth and duration of response to regorafenib (evaluated by RECIST 
v1.1. criteria) according to KEF and ctDNA drop.  
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Appendix to: Functional Imaging and circulating biomarkers of response to 
Regorafenib in treatment-refractory metastatic colorectal cancer patients in a 
PROSPECTive phase II study. 
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Methods 
Study inclusion criteria (as specified in trial protocol): 
1. In order to be eligible for registration, all inclusion criteria must be met. A patient must:  
 Understand, be willing to give consent, and sign the written informed consent form 
(ICF) prior to undergoing any study-specific procedure: 
  Be male or female and ≥ 18 years of age 
2. patients with a histologically confirmed diagnosis of metastatic colorectal 
adenocarcinoma, have RAS MT disease (Patients who are undergoing biopsies for 
diagnostic purposes will be allowed to participate in the study, as long as the diagnostic 
test confirms the evidence of RAS mutant disease) and have received the following 
treatment regimens described below: Previous treatment with fluoropyrimidine-
,oxaliplatin-, and irinotecan-based chemotherapy; and progressed following the last 
administration of approved therapy. Subjects who have discontinued treatment due to 
unacceptable toxicity will also be allowed into the study. 
 
3. patients with inoperable mCRC who are suitable for treatment with regorafenib as 
monotherapy and had: a CT or MRI scan (chest, abdomen, pelvis and other suspected 
sites as applicable) to determine eligibility for recruitment within 4 weeks prior to 
treatment (hereafter referred to as the “Eligibility scan”) 
4. patients who have metastatic disease sites which are amenable to core biopsy 
(preferably liver, soft tissue or nodal disease, with at least one lesion 1.5cm or more in 
diameter. If largest lesion 1-1.5cm diameter, eligibility to be discussed with radiologist 
prior to study entry)   
5. patients who have an Eastern Cooperative Oncology Group (ECOG) performance status 
of 0 or 1 within 28 days prior to the initiation of study treatment 
6. patients who have adequate bone marrow, liver function, and renal function, as 
measured by the following laboratory assessments conducted within 14 days prior to the 
initiation of study treatment: 
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 Total bilirubin < 1.5 times the upper limit of normal (ULN) 
 Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 
times the ULN in patients with no hepatic metastases and <5 the ULN in patients 
with hepatic metastatic disease. 
 Glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m2 according to the modified 
diet in renal disease (MDRD) abbreviated formula. 
 Platelet count 100000 /mm3, hemoglobin (Hb) 9 g/dL, absolute neutrophil count 
(ANC) ³ 1500/mm3  
 Lipase < 1.5 x ULN 
 International normalized ratio (INR) of prothrombin time (PT; PT-INR) and partial 
thromboplastin time (PTT)  1.5 times the ULN. Patients who are therapeutically 
treated with an agent such as warfarin or heparin will be allowed to participate if 
no underlying abnormality in coagulation parameters exists as per medical 
history. Weekly evaluation of PT-INR/PTT will be required until stability is 
achieved (as defined by local standard of care and based on pre-study PT-
INR/PTT values). The anti-coagulation therapy will be stopped 48 hours prior to 
the biopsy and re-commenced 24-48 hours after the procedure on 
recommendation of the interventional radiologist. Physicians will be strongly 
encouraged to switch oral coumadin derivatives (e.g. warfarin) to subcutaneous 
formulations, however if this was not possible due to any clinical reasons or 
patients preference, they will still be allowed on the study with careful monitoring 
of their INR and after discussion with the interventional radiologist performing the 
procedure. 
7. If female and of childbearing potential, have a NEGATIVE result on a pregnancy test 
performed a maximum of 7 days before initiation of study treatment; pregnancy status 
must be documented prior to the first dose of study treatment 
Page 38 of 85
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
4 
 
8.  If female and of childbearing potential or if male, must agree to use adequate 
contraception (e.g., abstinence, intrauterine device, oral contraceptive, or double-barrier 
method) based on the judgment of the investigator or a designated associate from the 
date on which the ICF is signed until 6 months after the last dose of study drug. 
 
Study exclusion criteria (as specified in trial protocol) 
A patient who meets ANY of the exclusion criteria will NOT be eligible for randomization. 
A patient must NOT 
 
1. have had prior treatment with regorafenib or any other VEGF-targeting kinase inhibitor 
2. have had previous or concurrent cancer that is distinct in primary site or histology from 
colorectal cancer within 2 years prior to recruitment EXCEPT for curatively treated 
cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta 
(Noninvasive tumor), Tis (Carcinoma in situ) and T1 (Tumor invades lamina propria)].  
3. Patients that are participating in another clinical trial involving an investigational 
medicinal product, unless it is more than 14 days after they have ceased the 
investigational medicinal product 
4. Patients that are participating in another research study involving tumour tissue biopsies 
planned to take place during the time that the patient is participating in this study 
5. Have had a major surgical procedure, open biopsy, or significant traumatic injury within 
28 days prior to initiation of study treatment 
6. If female and of childbearing potential, be engaged in breast feeding 
7. Be unable to swallow oral tablets (crushing of study treatment tablets is not allowed) 
8. Arterial or venous thrombotic or embolic events such as cerebrovascular accident 
(including transient ischemic attacks), deep vein thrombosis or pulmonary embolism 
within 6 month before the start of study medication (except for adequately treated 
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catheter-related venous thrombosis occurring more than one month before the start of 
study medication) 
9.  Interstitial lung disease with ongoing signs and symptoms at the time of informed 
consent. 
10. Ongoing infection > Grade 2 NCI CTCAE 
11. Uncontrolled hypertension (Systolic blood pressure > 140  mmHg or diastolic pressure > 
90 mmHg) despite optimal medical management  
12. Have congestive heart failure classified as New York Heart Association Class 2 or higher 
13. Have had unstable angina (angina symptoms at rest) or new-onset angina < 3 months 
prior to screening 
14. Have had a myocardial infarction < 6 months prior to initiation of study treatment 
15. Have cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta 
blockers, calcium channel blockers or digoxin 
16. Have pheochromocytoma 
17. Have a known history of human immunodeficiency virus infection 
18. Have either active hepatitis B or C or chronic hepatitis B or C requiring treatment with 
antiviral therapy 
19. have an active unstable seizure disorder with last episode of seizure within 4 weeks of 
starting the trial treatment 
20. Have had a hemorrhage or a bleeding event Grade 3 ( NCI-CTCAE v 4.0) within 4 weeks 
prior to the initiation of study treatment 
21. Have a non-healing wound, ulcer, or bone fracture 
22. Have renal failure requiring hemodialysis or peritoneal dialysis 
23. Have persistent proteinuria > 3.5 g/24 h, measured by urine protein:creatinine ratio from 
a random urine sample (Grade 3, NCI-CTCAE v 4.0) 
24. Have a substance abuse, medical, psychological, or social condition that may interfere 
with participation in the study or evaluation of the study results 
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25. Have a known hypersensitivity to any of the study drugs, study drug classes, or 
excipients in the formulation of the study drugs 
26. Have history of brain metastases 
Subject withdrawal criteria (as specified in trial protocol) 
 
Participation in this study is voluntary. Patients will be permitted to withdraw from the study 
at any time.  
 
If a patient’s scheduled dose of regorafenib treatment is delayed for more than 4 weeks for 
any reason, or if a patient ceases treatment because of toxicity, then the patient will 
withdraw from this study and will not be asked to undergo the second mandatory or the 
optional research biopsy, unless the patient has clinically and/or radiologically progressed. 
 
If a patient is not able to have a biopsy because they are no longer considered fit for biopsy, 
or there is no longer a site suitable for biopsy, then the patient will not be required to 
undergo further biopsies. This will need to be discussed with the Chief Investigator. These 
patients will be required to be replaced to complete 30 evaluable patients with paired 
biopsies; however, the clinical and translational data generated from the withdrawn patients 
will be reported as part of the study. 
 
If a patient loses capacity to consent during the study, then the patient would withdraw from 
the study.  
 
Should a patient withdraw from the study, then any biological material and data collected 
during the study period may still be analysed, unless the patient specifically requests that 
this does not occur. If the patient consents, serious adverse event data will continue to be 
collected for 30 days after the last procedure, even if the patient has withdrawn from the 
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study. Despite treatment withdrawal, patients will continue to be followed in the study. The 
frequency of follow-up is left to the clinician’s discretion. 
However, survival status should be ascertained at least once every 3 months which can be 
conducted over the telephone alone. 
 
 
MRI data acquisition 
All patients were scanned on a MAGNETOM Avanto 1.5T MR scanner (Siemens Healthcare, 
Erlangen, Germany) Before any post-processing, DCE-MRI liver data were manually 
registered (2D technique, in house software) to minimise any residual breathing effect. 
Regions of interest (ROIs) of the imaged target lesion were drawn, slice by slice, by a senior 
radiologist on high-b-value diffusion weighted images (b900) and translated to the DCE-MRI 
data. Voxel-wise analysis of the delineated ROIs was performed using in-house written 
software designed for each imaging technique [1]. For all imaging parameters, the results of 
each analysed image section were merged to obtain a volume of interest (VOI); the number 
of image sections (2-10) included in the VOI depended on the lesion size; the median value 
of VOI imaging parameters for every patient at each time point was reported. The ADC was 
calculated assuming a mono-exponential fitting algorithm.   
 
DCE protocol: A standard dose of contrast agent (Dotarem, 0.2 ml/kg) followed by 20 ml of 
saline was delivered by an automatic power injector at 3 ml/s. DCE-MRI data were acquired 
using a 3D fast field echo sequence with: 14 coronal partitions, slice thickness 5mm, TR/TE 
= 3/0.89 ms, flip angle = 11°, FOV=400x400 mm2, matrix=128x128, 1 average, parallel 
acquisition (Grappa acc. factor 2, ref  lines 24). Dynamic scans were preceded by a 
calibration scan with the same parameters, but at a lower flip angle (2°) and with 7 averages, 
to enable contrast quantification[2]. For abdominal disease sites, patients were imaged 
coronally using a sequential breath-hold technique optimised for liver lesions: two image 
volumes were acquired during each 6 s breath-hold, followed by a 6 s breathing gap; 40 
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volumes were acquired over 4.18 min[3]. For pelvic disease sites, patients were imaged 
axially with a free breathing technique: 80 image volumes acquired continuously at 3.3 s/vol 
for 4.4 min.  
DWI protocol: Pelvic (axial plane) and abdominal (coronal plane) DWI data were acquired in 
free breathing. The DWI parameters for liver acquisition were: 2D echo planar imaging  
sequence, 20 coronal slices, slice thickness 5 mm, TR/TE=5000/60 ms, FOV=400x400 mm2, 
5 independent acquisitions (no averaging), matrix 128x128, phase partial Fourier 7/8, 
parallel acquisition (GRAPPA acc. factor 2, ref lines 30), 8 b-values 
(0,20,40,60,120,240,480,900 s/mm2), diffusion times δ=14.6 ms and Δ=24 ms, total 
acquisition time ~2 min/acquisition. Similar axial acquisitions were acquired for the pelvic 
region.  
 
Isolation of circulating tumour (ct)DNA 
ctDNA was extracted from EDTA anti-coagulated blood within 1 h after collection, plasma 
was separated from the cells by centrifugation (1500g for 15 min at 4 °C) followed by a 
second centrifugation of the supernatant at 1500g for 10 min at 4 °C to remove all cell 
debris. If not used immediately, plasma was frozen at -80 °C until further processing. ctDNA 
from 2 ml of plasma was isolated by the use of Qiagen blood mini kit (Qiagen, Hilden, 
Germany) according to manufacturer’s protocol. 
 
Statistical Analysis 
1) Sample Size (as specified in trial protocol) 
Since this study was exploratory in nature and included two (or three) biopsies per patient, 
we kept the sample size low; to 20 patients with at least two biopsies; i.e. at baseline and at 
progression. Patients with stable disease or response after 8 weeks were required to have 
three biopsies. We planed to compare the tumour molecular signatures of patients at 
commencement of regorafenib with that at the time of progressive disease. It was expected 
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that 1 to 2 patients would be recruited per month. If any patient refused or withdrew before a 
second biopsy at the time of disease progression, then that patient was required to be 
replaced. The sample size was later expanded to 30 patients with paired biopsies through a 
protocol amendment as half of the patients progressed without any benefit from therapy. 
Although patients with primary progression would provide valuable information about the 
reasons behind primary progression but we optimised the sample size in order to have 
maximum information about the mechanisms of acquired resistance to regorafenib. As 
indicated in the main body of manuscript, patients meeting the criteria for MRI substudy were 
included in this cohort analysis. 
 
2) Statistical Analysis of plan on the study (as specified in trial protocol) 
 
 
The changes in the tumour molecular signature between commencement of regorafenib and 
development of resistance to the drug will be described at the time of data maturation. 
Resistance to regorafenib will be defined as the time that the patient ceases regorafenib 
therapy because of a clinical decision (made by the patient’s treating oncologists) to stop 
treatment due to progressive disease. 
 
Survival endpoints will be analysed using Kaplan Meier methods and median survival 
presented with 95% confidence intervals. PFS defined as time from start of regorafenib 
treatment to first progression or death of any cause. OS defined as time from start of 
regorafenib treatment to death of any cause. Patients who are event free at the time of 
analysis will be censored. 
 
Candidate genes in circulating free tumour DNA will be tested in the blood samples that are 
being collected every four weeks. Changes in the candidate genes across time will be 
described in all patients and also separately for those that achieve disease control and those 
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that progress (changes up to progression). We will particularly assess whether mutation 
detection in candidate drivers of regorafenib resistance correlated with primary resistance 
and whether such candidate resistance drivers become detectable before radiological 
progression is observed. This may allow the development of minimally invasive therapy 
stratification biomarkers.  
 
In the patients who have had a tumour biopsy at 8 weeks, the changes in the transcriptomic 
and genetic signature from baseline to disease control will be described. Disease control 
rate is defined as partial or complete response or stable disease according to RECIST 1.1. 
 
Objective response rate defined as partial or complete response according to RECIST 1.1 
will be summarised as a proportion with 95% confidence interval. Disease control is defined 
as objective response or stable disease. 
 
Efficacy endpoints (response and survival) will be summarised descriptively by histological 
growth patterns. Due to small numbers no formal statistical testing will be undertaken. 
  
Changes in the genomic landscape from the time of diagnosis of CRC (using archival tissue) 
to the biopsy taken before regorafenib treatment and finally until regorafenib resistance has 
developed will be described. This will provide the first insight into CRC evolution throughout 
multiple lines of combination chemotherapy, anti-angiogenic treatment and regorafenib 
therapy. This should provide critical data to define rational re-biopsy strategies throughout 
CRC patient pathways.  
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Supplementary Tables 
 
Appendix Table A1: Concordance between DCE-MRI and tissue biopsy. Liver lesions 
were chosen to optimise the chances of matched tissue analysis as the study involved 
repeated biopsies and liver is site that can be more conveniently subjected to multiple 
biopsies. We however didn’t find any significant differences in data interpretation depending 
upon site of metastatic disease. Interestingly, 1 patient with pelvic mass (patient 1), who had 
>70% drop in KEF was found to have PR with regorafenib. This was the only patient who 
achieved PR on the current cohort. 
Patient 
ID 
Biopsied Target 
Biopsy 
Guidance 
Concordance MRI-
Tissue Biopsy 
Time-lapse 
between BL MRI 
and biopsy 
 (less 1 week) 
1 left pelvis wall CT yes yes 
2 pelvis mass CT yes yes 
3 liver: segm 3 US yes yes 
4 liver: segm 6/7 US yes yes 
5 pelvic mass CT No (MRI of segm8liver) yes 
6 peritoneal CT/US No (MRI of segm1liver) yes 
7 liver: segm 5 CT yes no (9 days) 
8 liver: segm 5 CT/US yes yes 
9 liver: segm 7 US yes yes 
10 liver: segm 6 US yes yes 
11 liver: segm 7 CT yes yes 
12 liver: segm 5 US No (MRI of segm8liver) yes 
13 liver: segm 7/8 US yes yes 
14 liver: segm 8 US yes yes 
15 liver: segm 3 US yes yes 
16 liver: segm 6/7 US yes yes 
17 liver: segm 6 US yes yes 
18 liver: segm 2/3 US yes yes 
19 liver: segm  2 US yes yes 
20 liver: segm 6 US yes yes 
21 liver: segm 3 US yes yes 
22 liver: segm 7 US yes yes 
23 liver: segm 6 US yes yes 
24 liver: segm 6 US yes yes 
25 liver: segm 6/7 US yes yes 
26 liver: segm 6 US yes yes 
27 liver: segm 7 US yes yes 
 
Segm= segment; CT=Computed Tomography; US= Ultrasound; MRI=Magnetic Resonance 
Imaging; BL=baseline 
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Appendix Table A2: Summary of changes in DCE-MRI parameters 
 
 K
trans (nonzeros) 
[min-1] 
IAUGC60 
[mmol∙s] 
EF 
[%] 
KEF 
[min-1] 
Baseline        
Mean (sd) 0.14 (0.08) 11.91 (6.01) 88.05 (13.14) 0.13 (0.08) 
Median (IQR) 0.11 (0.09 - 0.19) 10.96 (7.07 - 
15.26) 
92.29 (82.75 - 
99.31) 
0.11 (0.07 - 0.18) 
Range 0.06 - 0.37 2.75-27.87 50.81 - 100.00 0.03 - 0.33 
        
        
C1D15        
Mean (sd) 0.10 (0.07) 5.66 (4.08) 57.86 (23.09) 0.06 (0.05) 
Median (IQR) 0.07 (0.07 - 0.10) 5.05 (2.79 - 
7.04) 
57.94 (41.01  -
77.92) 
0.05 (0.03 - 0.07) 
Range 0.03 - 0.38 2.04 - 21.97 21.99- 96.87 0.01 - 0.27 
        
        
Percentage 
decrease 
       
Mean (sd) 25.20 (34.56) 49.26 (24.58) 34.31 (24.22) 51.29 (27.42) 
Median (IQR) 27.75 (6.74 - 
52.56) 
57.70 (32.66 - 
67.93) 
35.33 (12.40 - 
56.19) 
58.28 (28.28 - 76.14) 
Range -63.22 - 82.32 -1.71 - 77.68 -14.03 - 74.76 -5.55 - 93.76 
        
EF= enhancing fraction; IQR= inter-quartile range; sd=standard deviation; C1D15= cycle 1, 
day 15, KEF= product of summarised median values of Ktrans (nonzeros) x EF; IAUGC60= 
initial area under the gadolinium concentration-time curve over 60 seconds  
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Appendix Table A3: ROC curve analysis to choose clinically appropriate KEF drop 
 
Cut point Sensitivity Specificity Correctly 
Classified 
    
  5.55   100.00% 0.00% 60.87% 
 -4.63     92.86% 0.00% 56.52% 
-10.01     85.71% 0.00% 52.17% 
 -14.38     85.71% 11.11% 56.52% 
-17.87     85.71% 22.22% 60.87% 
-18.25     78.57% 22.22% 56.52% 
-28.27     78.57% 33.33% 60.87% 
-32.49     71.43% 33.33% 56.52% 
-41.55     71.43% 44.44% 60.87% 
-45.47     71.43% 55.56% 65.22% 
-51.59     71.43% 66.67% 69.57% 
-53.69     64.29% 66.67% 65.22% 
-58.28     57.14% 66.67% 60.87% 
-65.25     57.14% 77.78% 65.22% 
-66.37     50.00% 77.78% 60.67% 
-67.12     50.00% 88.89% 65.22% 
-69.21      50.00% 100.00% 69.57% 
-70.99     42.86% 100.00% 65.22% 
-77.37     35.71% 100.00% 60.87% 
-77.94     28.57% 100.00% 56.52% 
-78.86     21.43% 100.00% 52.17% 
-82.04     14.29% 100.00% 47.83% 
-93.76       7.14% 100.00% 43.48% 
-93.76        0.00% 100.00% 39.13% 
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Appendix Table A4: Correlation between KEF and CD31 drop 
  Drop in KEF    
CD31 No Yes Total 
No change 7 (54%) 0 7 (37%) 
Drop (i.e. >5% drop from baseline) 6 (46%) 6 (100%) 12 (63%) 
Total 13 (100%) 6 (100%) 19 (100%) 
        
 Fisher's exact, p=0.04  
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Appendix Table A5: KEF (Ktrans * EF/100) according to RECIST response (70%) 
 Responder (CR/PR/SD) Total 
(n=23) No   (n=9) Yes   (n=14) 
No KEF Drop 9 8 17 
KEF Drop  0 6 6 
Fisher's exact p-value 0.048 
Sensitivity, 95% CI 42.9% (17.7-71.1%) 
Specificity, 95% CI 100% (66.4-100%) 
Accuracy 65.2% 
OR (95% CI) NE (1.46-NE) 
CI=confidence interval; CR= complete response; n=number; NE= not evaluable; OR= odds 
ratio; PR= partial response; RECIST=response evaluation criteria in solid tumours; SD= 
stable disease  
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Appendix Table A6: KEF (Ktrans * EF) and correlation with clinical efficacy parameters 
 
 
 No KEF drop KEF Drop 
PFS 
Events 16/17 6/6 
Median PFS (95% CI), 
months 
2.0 (1.8-3.9) 5.6 (3.8-NE) 
4 months PFS 23.5% (7.3%- 44.9%) 66.7% (19.5% - 90.4%) 
6 months PFS NE 50.0% (11.9% - 80.4%) 
HR (95% CI) reference 0.16 (0.04-0.72), 
p=0.02 
   
OS   
Events 12/17 3/6 
Median OS (95% CI), 
months 
5.5 (3.4-6.1) 15.2 (6.1-NE) 
4 months OS 69.0 (40.8% - 85.5%) 100% (NE) 
6 months OS 27.6% (7.2% - 53.2%) 100% (NE) 
1 year OS 13.8% (1.0% - 42.5%) 75.0% (12.8% - 96.1%) 
HR (95% CI) reference 0.08 (0.01-0.63), 
p=0.02 
 
CI=confidence interval; HR= hazard ratio; PFS= progression free survival; OS=overall 
survival 
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Appendix Table A7: Apparent Diffusion Coefficient (ADC) changes on day 15 
Number Baseline 
 
 
[10-5 
mm2/s] 
C1D15 
 
 
[10-5 mm2/s] 
Relative 
change from 
baseline 
[%] 
 
Response 
1 101.81 99.03 2.73 0 
2 106.83 97.27 8.95 0 
3 78.93 100.22 -26.97 0 
4 93.77 103.6 -10.48 0 
5 108.47 117.04 -7.90 0 
6 112.76 114.75 -1.76 0 
7 116.47 125.17 -7.47 0 
8 85.14 86.24 -1.29 0 
9 116.19 119.26 -2.64 0 
10 120.72 124.77 -3.35 0 
11 112.63 161.71 -43.58 0 
12 91.55 103.8 -13.38 0 
13 83.82 94.39 -12.61 0 
14 118.67 124.74 -5.12 0 
15 140.07 150.18 -7.22 0 
16 117.57 127.01 -8.03 0 
17 98.66 91.16 7.60 0 
18 121.47 134.12 -10.41 0 
19 124.64 141.39 -13.44 0 
20 93.21 118.44 -27.07 0 
21 102.08 107.04 -4.86 0 
22 102.19 131.36 -28.54 0 
23 94.15 111.29 -18.20 0 
24 93.5 99.88 -6.82 0 
25 95.65 99.01 -3.51 0 
26 114.44 124.14 -8.48 0 
27 77.73 83.83 -7.85 0 
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Appendix Table A8: Association of progression free survival with 
clinical/haematological factors  
 Group A Group B 
PFS in months according to Platelets 
 <median (261)  ≥median (261)  
Events 8/11 7/12 
Median PFS (95% CI), 
months 
3.9 (1.8-5.6) 2.0 (1.8 – 4.9) 
HR (95% CI) reference 
1.02 (0.42-2.48), 
p=0.953 
   
PFS in months according to NLR 
 <median (4.46)  ≥median (4.46)  
Events 5/11 10/12 
Median PFS (95% CI), 
months 
3.9 (1.8-5.6) 2.0 (1.8 – 4.9) 
HR (95% CI) reference 
1.50 (0.63-3.59), 
p=0.364 
   
PFS in months according to line of treatment 
 <2 lines  >2 lines  
Events 7/11 8/12 
Median PFS (95% CI), 
months 
1.9 (1.6-3.9) 3.9 (1.9-6.1) 
HR (95% CI) reference 
0. 43 (0.16-1.11), 
p=0.80 
   
PFS in months according to Performance Status 
 PS0  PS1  
Events 4/7 11/16 
Median PFS (95% CI), 
months 
3.6 (1.8-NE) 3.5 (1.8-4.2) 
HR (95% CI) reference 
2.27 (0.74-694), 
p=0.150 
 
CI=confidence interval; HR= hazard ratio; PFS= progression free survival; NLR= 
Neutrophil/Lymphocyte Ratio; PS=Performance Status 
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Appendix Table A9: Association of overall survival with clinical/haematological 
factors 
 Group A Group B 
OS in months according to Platelets 
 <median (261)  ≥median (261)  
Events 8/11 7/12 
Median OS (95% CI), 
months 
5.8 (4.7-6.1) 13.3 (2.9-NE) 
HR (95% CI) reference 
0. 72 (0.25-2.12), 
p=0.554 
   
OS in months according to NLR 
 <median (4.46)  ≥median (4.46)  
Events 5/11 10/12 
Median OS (95% CI), 
months 
6.1 (2.7-NE) 5.7 (3.4-6.1) 
HR (95% CI) reference 
1.52 (0.50-4.67), 
p=0.463 
   
OS in months according to line of treatment 
 <2 lines  >2 lines  
Events 7/11 8/12 
Median OS (95% CI), 
months 
4.8 (2.7-NE) 6.1 (3.4-NE) 
HR (95% CI) reference 
0. 44 (0.14-1.33), 
p=0.146 
   
OS in months according to Performance Status 
 PS=0  PS=1  
Events 4/7 11/16 
Median OS (95% CI), 
months 
13.3 (2.7-NE) 5.7 (4.7-6.1) 
HR (95% CI) reference 
2.82 (0.75-10.6), 
p=0.124 
 
CI=confidence interval; HR= hazard ratio; OS= overall survival; NLR= 
Neutrophil/Lymphocyte Ratio; PS=Performance Status 
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Appendix Table A10: Summary of dose adjustments required on the study 
 
Dose 
reductions* 
   
Cycle Yes % Total 
C1D1 0 0.0% 27 
C1D15 1 4.0% 25 
C2 14 58.3% 24 
C3 5 38.5% 13 
C4 2 15.4% 13 
C5 2 33.3% 6 
C6 0 0.0% 4 
C7 0 0.0% 2 
C8 0 0.0% 2 
C9 0 0.0% 2 
C10 0 0.0% 2 
C11 0 0.0% 1 
C12 0 0.0% 1 
C13 0 0.0% 1 
C14 0 0.0% 1 
    
Dose Delays†    
Cycle Yes % Total 
C1D1 0 0.0% 27 
C1D15 0 0.0% 25 
C2 4 16.7% 24 
C3 6 46.2% 13 
C4 1 7.7% 13 
C5 0 0.0% 6 
C6 1 25.0% 4 
C7 0 0.0% 2 
C8 0 0.0% 2 
C9 0 0.0% 2 
C10 0 0.0% 2 
C11 0 0.0% 1 
C12 0 0.0% 1 
C13 0 0.0% 1 
C14 0 0.0% 1 
    
Missed days¥    
Cycle Yes % Total 
C1D1 11 40.7% 27 
C1D15 10 40.0% 25 
C2 7 29.2% 24 
C3 5 38.5% 13 
C4 4 30.8% 13 
C5 2 33.3% 6 
C6 2 50.0% 4 
C7 0 0.0% 2 
C8 0 0.0% 2 
C9 0 0.0% 2 
C10 0 0.0% 2 
C11 0 0.0% 1 
Page 55 of 85
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
21 
 
C12 1 100.0% 1 
C13 1 100.0% 1 
C14 0 0.0% 1 
 
*96% and 4% of patients required dose reductions due to non-haematological and 
haematological toxicities respectively. When dose reduction was required, patients were 
offered 120mg and 80 mg on first and second dose reductions respectively. Patients came 
off the study if further dose reduction was required. †58% of patients required dose delays 
due to non-haematological toxicities and 33% for other logistical reasons. ¥Median days 
missed on treatment were 6 (4-9) days, mean 7(minimum 1 and maximum 14 days). 
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Appendix Table A11: Summary of grade 3-5 toxicities on the study 
 
Reported Toxicity Grade 3-5 
  
 No. % 
Rectal perforation* 1 4 
Skin rash (desquamation) 1 4 
Anaemia 2 7 
Diarrhoea 2 7 
Haemorrhage 2 7 
Fatigue 4 15 
Mucositis 3 11 
Hand foot syndrome 6 22 
Infection 6 22 
   
*This was the only grade 5 toxicity in the reported cohort 
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Appendix Table A12: Dose adjustments and efficacy outcomes in patients with >70% 
KEF drop 
  Drop in KEF    
Any dose reduction ≥50% No Yes Total 
No 14 (82.3%) 2 (33.3%) 16 (69.6%) 
Yes 3 (17.7%) 4 (66.7%) 7 (30.4%) 
Total 17 (100%) 6 (100%) 23 (100%) 
      Fisher's exact, 
p=0.045  
   
    
Any delay No Yes Total 
No 13 (76.4%) 2 (33.3%) 15 (65.3%) 
Yes 4 (23.6%) 4 (66.7%) 8 (34.7%) 
Total 17 (100%) 6 (100%) 23 (100%) 
      Fisher's exact, 
p=0.131   
  
Number of cycles >2 No Yes Total 
No 10 (58.8%) 0 (0%) 10 (65.3%) 
Yes 7 (41.2%) 6 (100%) 13 (34.7%) 
Total 17 (100%) 6 (100%) 23 (100%) 
      Fisher's exact, 
p=0.019   
KEF= Ktrans * EF 
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Supplementary Figures 
 
 
Appendix Figure A1: Waterfall plot representing KEF drop after 15 days of treatment in 
responders and non- responders patients 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure A1: Waterfall plot of drop vs. no drop in KEF (70%) according to disease 
control rate measured by RECIST v1.1 at 2 months after initiation of therapy; the blue colour 
key indicates response (defined as stable disease or partial response by RECIST 1.1) and 
grey key indicates progressive disease. 
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Appendix Figure A2: Outcome according to CD-31 drop after 2 months of treatment in the 
PROSPECT-R Trial 
 
 
 
 
 
Appendix Figure A2: Kaplan-Meier curves for progression-free survival (A) and overall 
survival (B) in patients with or without CD-31 drop. 
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ABSTRACT 
Objective: Regorafenib demonstrated efficacy in metastatic colorectal cancer 
(mCRC) patients. Lack of predictive biomarkers, potential toxicities and cost 
effectiveness concerns highlight the unmet need for better patient selection.  
Design: RAS mutant mCRC patients with biopsiable metastases were enrolled in 
this phase II trial. Dynamic contrast enhanced (DCE) MRI was acquired pre and at 
day 15 post-treatment. Median values of volume transfer constant (Ktrans), enhancing 
fraction (EF) and their product KEF (summarised median values of Ktrans x EF) were 
generated. Circulating tumour (ct) DNA was collected monthly until progressive 
disease and tested for clonal RAS mutations by digital-droplet PCR. Tumour 
vasculature (CD-31) was scored by immunohistochemistry on 70 sequential tissue 
biopsies.  
Results: Twenty seven patients with paired DCE-MRI scans were analysed. Median 
KEF decrease was 58.2%. Of the 23 patients with outcome data, >70% drop in KEF 
(6/23) was associated with higher disease control rate (p=0.048) measured by 
RECIST v1.1 at 2 months, improved progression free survival (PFS) [Hazard ratio 
(HR) 0.16 (95% CI 0.04-0.72), p=0.02], 4-month PFS (66.7% vs. 23.5%) and overall 
survival (OS) [HR 0.08 (95% CI 0.01-0.63), p=0.02]. KEF drop correlated with CD-31 
reduction in sequential tissue biopsies (p=0.04). RAS mutant clones decay in ctDNA 
after 8 weeks of treatment was associated with better PFS [HR 0.21 (95% CI 0.06 - 
0.71), p=0.01] and OS [HR 0.28 (95% confidence interval 0.07 - 1.04), p=0.06].  
Conclusions: Combining DCE-MRI and ctDNA predicts duration of anti-angiogenic 
response to regorafenib and may improve patient management with potential 
health/economic implications.  
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Significance of the Study 
What is already known on this subject? 
• Regorafenib is approved as third-line therapy for patients with refractory CRC; 
however, its use in the clinic has been restricted due to modest clinical benefit 
in unselected patients.  
• Published pre-clinical studies suggested that anti-angiogenic activity of 
regorafenib is the main pre-determinant of its efficacy but no clinical studies 
have validated these findings. 
• Retrospective analysis of prospective clinical trials failed to identify 
biomarkers od response to regorafenib that might be implemented in clinical 
practice. 
 
What are the new findings? 
• Regorafenib showed significant activity in patients with marked early anti-
angiogenic response, resulting in a longer disease control, better PFS and 
OS.  
• Early (day 15 post-treatment) DCE-MRI predicts response and long term 
outcome during Regorafenib treatment.  
• Sequential analysis of tissue biopsies confirmed that reduction in tumour 
vasculature as the mechanism underpinning the observed radiological 
findings.  
• Persistent regorafenib-induced anti-angiogenic effect translates into a 
reduction in circulating tumour (ct) DNA and this might be incorporated into 
the clinical algorithm for patients’ management.   
 
Implications on clinical practice 
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Implementing the use of DCE-MRI and ctDNA analysis as early biomarkers of 
response to regorafenib might improve patient selection with clear health/economic 
implications for patients, health systems and society. 
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Introduction 
Colorectal cancer (CRC) remains a major health burden with significant morbidity 
and mortality despite recent improvements in its management owing to better 
screening and therapeutic options[1]. CRC is known to be a biologically 
heterogeneous disease characterised by the activation of several angiogenic and 
oncogenic pathways[2]. Regorafenib, a multikinase inhibitor (MKI) with known anti-
angiogenic, anti-stromal and anti-oncogenic activities[3], has demonstrated single 
agent efficacy in patients with treatment refractory metastatic CRC (mCRC)[4, 5]. 
The use of regorafenib in the clinic is however hampered by the modest efficacy in 
an unselected patient population, a significant side effect profile and the high drug 
costs. Consequently, identification of predictive biomarkers of response and 
resistance to regorafenib is critical for treatment stratification and appropriate patient 
selection such that treatment benefits could be optimised. 
Several efforts are currently ongoing to define gene signatures [6] and bio-markers of 
response to anti-angiogenic drug in CRC and other cancers[7]; however, ongoing 
validation will only determine the use of these biomarkers in clinical practice. Whilst 
recent studies utilising tissue [8] and plasma [9, 10] have attempted to elucidate the 
response and resistance mechanisms to regorafenib, the search for a clinically useful 
biomarker has been largely unsuccessful. A growing body of pre-clinical evidence 
suggests strong anti-angiogenic and pro-apoptotic effects of regorafenib [11, 12, 13, 
14] with clinical data demonstrating that drug activity is independent of the tumour’s 
mutational status[8]. These findings strengthen the hypothesis that additional 
mechanisms other than oncogenic blockade are responsible for the anti-tumour 
activity of this drug. Dynamic contrast enhanced magnetic resonance imaging (DCE-
MRI) may have a useful role in evaluating tumour vascular heterogeneity and early 
anti-angiogenic effects[15],[16]; moreover, its parameters volume transfer constant 
(Ktrans), enhancing fraction (EF), and initial area under the gadolinium concentration-
time curve over 60 seconds (IAUGC60) have been correlated with micro-vessel 
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density and in some tumours with degree of VEGF expression [17]. By contrast, 
diffusion weighted MRI (DW-MRI) offers useful information that reflects tumour 
cellularity and increase in its quantitative parameter Apparent Diffusion Coefficient 
(ADC) has been associated with tumour cell death and necrosis[18, 19]. At least two 
pre-clinical studies demonstrated that regorafenib was able to significantly suppress 
tumour vascularity when quantified by DCE computed tomography (CT) and MRI 
modalities respectively in human colon carcinoma xenograft models[14, 20].  
In this prospective phase II trial of patients with RAS mutant mCRC treated with 
single agent regorafenib we hypothesised that 1) an early anti-angiogenic and anti-
proliferative activity of regorafenib might be detected by multi-parametric DCE-MRI 
on day 15 of the treatment 2) the depth of anti-angiogenic response detected by a 
significant drop in DCE-MRI quantitative parameters might correlate with clinical 
efficacy 3) analysis of sequential tissue and liquid biopsies could be integrated into 
the biomarker discovery process and shed insights into mechanisms of response to 
regorafenib. 
 
Material and Methods  
Clinical Trial Design 
PROSPECT-R trial (clinical trials.gov number [NCT03010722],) is a phase II, open 
label, non-randomised study of regorafenib in patients with RAS mutant, chemo-
refractory mCRC (Fig. 1). Patients who were at least 18 years old and had a World 
Health Organisation (WHO) performance status (PS) of 0-1, were deemed eligible if: 
all conventional treatment options including fluorouracil, irinotecan, oxaliplatin and at 
least one anti-VEGF drugs (later trial protocol was amended due to changes in 
availability of anti-VEGF agents due to funding restrictions in UK) were exhausted; 
they had metastatic tumour amenable to biopsy and repeat measurements with DCE-
MRI. Written informed consent was obtained from all patients. The study was carried 
out in accordance with the Declaration of Helsinki and approved by National 
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Institutional review boards [Medicines and Healthcare products Regulatory Agency: 
15983/0249/001-0001]. All participants were required to have mandatory pre-
treatment biopsies (6 cores targeted towards the MRI identified index lesion), 
biopsies at 2 months [if response or stable disease by RECIST v1.1 criteria (6 cores)] 
and at the time of progression (6-12 cores from two suitable progressing metastatic 
sites). 3 out of 6 cores were snap-frozen; one core was used to establish patient- 
derived organoids and two cores were formalin fixed and paraffin embedded (FFPE). 
The results section describes the number of cores used for immunohistochemistry 
analysis in the current study. Further genomic, transcriptomic and functional analyses 
are on-going on the remaining cores. Patients with suitable metastatic disease 
(defined as lesions at least 2 cm in diameter) and no contraindications to MRI 
underwent multiparametric MRI studies including matched DCE and DWI; images 
were acquired less than 7 days prior to therapy and at day 15 post-treatment. 
Treatment consisted of regorafenib 160mg once daily on a schedule of three weeks 
on and one week off until progression or intolerable side effects. More details on 
inclusion and exclusion criteria and criteria for patients’ withdrawal on the study are 
provided in the online supplementary material. 
 
MRI data processing: 
DCE-MRI data were post-processed using the Magnetic Resonance Imaging 
Workbench software developed at our institution [21]. The pharmacokinetic analysis 
was based on the extended Kety/Tofts model in conjunction with a cosine-based 
arterial input function (AIF) model derived from population-averaged values[22, 23]. 
DCE-MRI parameters including Ktrans, IAUGC60 and the EF were obtained for 
pre/post-treatment datasets. Ktrans estimates were reported for both whole tumour 
[Ktrans(all)] and valid voxels only [Ktrans(nonzeros), i.e. excluding all non-enhancements 
and non model-fits] in order to address the extended necrosis observed in the cohort. 
The EF was defined as percentage of the voxels that enhance above the noise floor 
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out of all tumour voxels. A voxel was considered enhancing when it’s post-contrast 
(Dotarem, Guerbet, France) dynamic intensity signal was at least one standard 
deviation higher than the mean pre-contrast signal, for a period of 60s post contrast 
onset.  Finally, volume change in tumour enhancement during therapy (such as new 
necrosis) was accounted for by reporting a composite parameter, KEF, which is the 
product of summarised median values of KEF= Ktrans (nonzeros) x EF[24]. For KEF, 
an ROC curve analysis was performed to establish the cut off able to identify 
meaningful clinical benefit based on disease control rate (DCR), progression free 
survival (PFS) and overall survival (OS).  
 
Digital Droplet (dd) PCR  
The QX200 ddPCR system (Bio-Rad, Berkeley, California) was used and all 
reactions were prepared using the ddPCR Supermix with no dUTTP for Probes. All 
PCR reactions were performed as duplex PCR using the relevant digital PCR assays 
for the wild-type and the mutation in question. Droplets were generated using the 
QX200 droplet generator according to the manufacturer’s protocols. The PCR 
reaction was performed in a C1000 Touch Thermo Cycler (Bio-Rad) using the 
following protocol: 95°C for 10 min followed by 40 cycles of 94°C for 30 sec and 55°C 
for 1 min, then 98°C for 10 min. Droplets were read in the QX200 droplet reader and 
analyzed using the Quantasoft software version 1.6.6.0320 (Bio-Rad). Fractional 
Abundance (FA) was defined as follows: F.A. % = (Nmut/(Nmut + Nwt)) × 100), 
where Nmut is the number of mutant events and Nwt is the number of WT events per 
reaction. The number of positive and negative droplets was used to calculate the 
concentration of the target and reference DNA sequences and their Poisson-based 
95% confidence intervals. ddPCR analysis of normal control plasma DNA (from cell 
lines) and no DNA template controls were always included. Samples with very low 
positive events were repeated at least twice in independent experiments to validate 
the obtained results as previously described[25]. 
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CD31, Ki-67 and Caspase-3 immunohistochemical staining 
The immunohistochemical expression of microvascular density (CD31; clone 
ab28364, Abcam, Cambridge, UK; dilution 1:50), cell proliferation (Ki-67; clone 
ab16667, Abcam; dilution 1:100), and cell apoptosis (Cleaved Caspase-3 (Asp175) 
(5A1E) ab9664S, Abcam; dilution 1:100) was examined on consecutive 4-µm 
formalin-fixed and paraffin-embedded (FFPE) sections of the neoplastic cores. 
Reactions were performed using the automated Benchmark® XT platform (Ventana 
Medical Systems, Basel, Switzerland). Appropriate positive and negative controls 
were run concurrently. 
For assessment of tumour microvascular density, CD31-positive micro-vessels were 
quantified and reported as the average number in 10 random fields at 200x 
magnification. Ki-67 labelling index was assessed as the average number of 
proliferating cells in 10 random fields at 200x magnification. Caspase-3 evaluation 
was categorized as positive or negative.  
Statistical Analysis  
The Disease Control Rate (DCR) was defined by the sum of complete responses 
(CR) + partial responses (PR) + stable diseases (SD) using RECIST v1.1. PFS was 
measured from start of treatment to date of progression or death from any cause. OS 
was defined as time from start of treatment to death of any cause. Patients without 
an event were censored at last follow up. Response according to KEF (Ktrans 
(nonzeros) x EF) was defined as a drop of >70% from baseline whilst change in 
CD31 biomarker levels from baseline was calculated as [(8wks-baseline)/ baseline] 
*100. CD31 change from baseline was explored on a continuous scale and was also 
dichotomised using the median value. 
Response according to KEF parameter and the dichotomised CD31 change from 
baseline were cross-tabulated with the RECIST measured DCR. Chi2 or Fisher’s 
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exact tests were employed to explore whether there is an association between them 
and DCR. Logistic regression was employed to produce odds ratios (ORs) and 95% 
confidence intervals (CIs). The PFS and OS rates were estimated using the Kaplan-
Meier method and survival curves were generated for each group. The log-rank test 
was used to compare the survival curves and a Cox proportional hazards model was 
fitted to obtain hazard ratios (HRs) and 95% CIs. The proportional hazards 
assumption was tested with the use of Schoenfeld residuals. 
In our study, despite relatively small study cohort, the changes in Ktrans and KEF 
values were noticeably larger (e.g. > 50% reduction in mean and median KEF). 
Based on results of the 23 analysable patients evaluated by DCE-MRI in our study, 
our patient sample size by post-hoc analysis (based on Wilcoxon-signed rank test) 
demonstrated 100% power to detect this difference at a level of significance of 0.05. 
 
Additional Methods can be found in the Online Appendix  
 
Results 
Patients’ characteristics and tissue collection 
Twenty seven treated patients (63% males) were recruited in the DCE-MRI 
PROSPECT-R trial and a total of 143 cores were collected by tissue biopsies from 70 
metastatic lesions for the current analysis. Right and left sided primary cancers were 
equally distributed in the study population; other relevant patient characteristics are 
summarised in Table 1.  
Fifty-four tissue cores were obtained from BL biopsies of 27 treated (27 lesions) 
patients; of the 14 patients with SD at 8 weeks, 24 tissue cores were obtained from 
12 (12 lesions) patients (one patient missed the biopsy due to a hospital admission 
secondary to chest infection and the other developed treatment related rectal wall 
perforation). A further 65 tissue cores were obtained from 23 evaluable patients (35 
lesions in total; 12 patients with two progressing lesions each) with PD (3 patients did 
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not complete 2 cycles of treatment and 1 came off due to treatment related rectal wall 
perforation). There was 89% concordance between target DCE-MRI and biopsied 
metastatic lesions (Appendix Table A1). Two FFPE cores per patient were tested at 
each time-point. One-hundred and nine plasma samples were tested to track RAS 
mutant clones in 21 corresponding patients; patients were required to have at least 
one sample available at 2 months following treatment.  
 
Radiological and pathological evidence of early regorafenib induced anti-
angiogenic effects 
A significant drop in all DCE-MRI parameters was seen after 2 weeks of treatment; 
median Ktrans, IAUGC60, EF and KEF product
 decreased by 27.8% [interquartile range 
(IQR) 6.7-52.6], 57.7% (32.7-67.9), 35.3% (12.4-56.2) and 58.3% (28.3-76.1) 
(Appendix Table A2). The ROC curve analysis performed for the KEF showed that a 
69.21% reduction from baseline had 100% specificity and overall accuracy of 
69.57%; for pragmatic reasons a minimum KEF product reduction of 70% was 
chosen (Appendix Table A3). Matched tissue analysis revealed a strong 
concordance between a drop in KEF and mean vascular density of tissue, as 
measured by CD31 count obtained pre-treatment and at 8 weeks in patients with 
tissue and MR parameter data available (p=0.04). (Appendix Table A4).   
 
Correlation of functional imaging data and CD31 staining with clinical 
parameters 
After a median follow up of 14.3 months [(95% CI 4.9 – not evaluable (NE)], IQR 4.9- 
not reached (NR)], 23 patients, who had at least 1 cycle of regorafenib and a 
response assessment by computed tomography (CT) scan at 2 months were 
analysable. DCR at 2 months, median PFS and median OS were 51.9%, 3.6 months 
(95% CI 1.9-4.2 months) and 5.8 months (95% CI 4.7-13.3 months) respectively; 
77.4% (95% CI 54.0-89.9%), 48.0% (95% CI 24.1-68.5%) and 32.0% (95% CI 11.2-
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53.4%) of patients were alive at 4, 6 and 12 months respectively. Patients with >70% 
drop in KEF (8/27; 2 patients didn’t undergo the 2 month scan due to treatment-
related toxicities and thus were excluded from the final analysis as per the study 
protocol) were found to have higher DCR (6/6 vs. 0/6, p=0.05) at 2 months (Appendix 
Table A5), better PFS [HR 0.16 (95% CI 0.04-0.72), p=0.02], better PFS at 4-months 
(66.7% vs. 23.5%) and better OS [HR 0.08 (95% CI 0.01-0.63), p=0.02]. For the 
group with >70% drop in KEF, 6-month and 12-month OS were 100% (95% CI NE) 
and 75% (95% CI 12.8% - 96.1%) respectively compared to 27.6% (7.2-53.2%) and 
13.8% (1.0-42.5%) in the <70% drop in KEF group (Fig 2A-B; Appendix Figure A1 
and Appendix Table A6). In order to address the relative improvement in efficacy with 
or without KEF drop, we compared the outcomes of all the patients who achieved 
DCR; PFS was found to be 5.6 vs. 4.2 months [HR 0.30 (95% CI 0.06-1.49), 
p=0.140) and OS was 15.2 vs. 5.8 months [HR 0.11 (95% CI 0.01-1.06), p=0.057] in 
this analysis. Interestingly, when the same analysis was repeated with the cut-off 
chosen by ROC analysis (69.21%), PFS [HR 0.18 (95% CI 0.03-0.91), p=0.038] and 
OS [HR 0.11 (95% CI 0.01-1.01), p=0.051] were found to be statistically significant 
despite small numbers.   
A decrease in CD31 score at 2 months was associated with higher DCR [OR 30.0 
(95% CI 2.22- 405.98), p=0.01], better PFS [HR 0.13 (95% CI 0.03- 0.52), p=0.004] 
and better OS [HR 0.30 (95% CI 0.08- 1.06), p=0.06] (Appendix Fig. A2). Examples 
of KEF drop, RECIST 1.1 response and CD31 scoring at different time-points in a 
responder (Fig. 3A-C) and non-responder patient (Fig. 3D-F) are provided.  
 
Radiological and pathological analysis of proliferation and apoptosis following 
regorafenib treatment 
Radiological cell kill effects of regorafenib were investigated by examining the 
changes in ADC on DW-MRI, pre-treatment and at day 15. Matching tissue was 
scored for cell proliferation (KI-67 index) and apoptosis (caspase 3) at pre-treatment 
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and 2 months post therapy. Median ADC changes are described in Appendix Table 
A7. The changes at 2 months in corresponding tissue parameters of cell proliferation 
was not associated with an improvement in DCR [OR 1.13 (95% CI 0.14-9.0), 
p=0.91], PFS [HR 1.11 (95% CI 0.35- 3.58), p=0.86] or OS [HR 0.91 (95% CI 0.19-
4.42), p=0.91], similarly no significant changes in apoptosis were observed when 
comparing baseline and 2 months treatment tissue biopsies. 
 
Liquid biopsy as a surrogate marker of response to regorafenib  
We hypothesised that regorafenib-induced anti-angiogenic effects would correlate 
with a reduction in ctDNA. Indeed, in a patient with significant (71%) KEF drop after 2 
weeks of treatment (Fig. 4A) and durable RECIST v1.1. response lasting nearly 12 
months (Fig. 4B-D), we observed that not only did the KEF reduction correlated with 
CD31 drop (Fig. 4E) but was also associated with a rapid and marked decrease in 
KRAS G12D ctDNA which persisted for the entire duration of the treatment and 
increased again when the treatment was halted due to a complication (Fig. 4F).  
Intriguingly, the changes in CEA lagged behind the changes in ctDNA. 
To test this hypothesis we analysed changes in RAS mutant clones in sequential 
liquid biopsies by ddPCR. We examined whether a drop in fractional abundance (FA) 
was associated with clinical efficacy parameters. We found that the loss of detectable 
mutant RAS clones in ctDNA after 4 weeks was universal to all the examined 
patients [(n=21) data not shown]. However, a sustained drop in ctDNA was observed 
in 47.6% of the patients at 2 months and was associated with better median PFS [HR 
0.21 (95% CI 0.06 - 0.71), p=0.01] and OS [HR 0.28 (95% CI O.07-1.04), p=0.06] 
respectively (Fig. 5A and 5B); PFS was 60.0% (after 4 months) and 40.0% (after 6 
months) in the groups with decrease in FA. In a multivariate analysis adjusting for 
KEF reduction, this effect was associated with better PFS [HR 0.23 (95% CI 0.07-
0.75), p=0.02]. 
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Despite the small numbers, which precluded any statistical analysis, it was 
remarkable to observe that patients with a KEF drop >70% and decrease in ctDNA 
FA had the most durable response to regorafenib (Fig. 5C) 
 
Known biomarkers of benefit from Regorafenib, toxicity profile and clinical 
outcome in the PROSPECT-R trial. 
A previously well conducted study comprising of 208 regorafenib treated patients 
demonstrated an association between high neutrophil, high platelet, low lymphocyte 
count and/or high neutrophil lymphocyte ration (NLR) with prognosis [26]. Due to the 
stringent inclusion criteria of our study, our data distribution did not allow to use the 
same cut of used in the study be Del Prete and colleagues and median values were 
used instead. Notwithstanding small numbers and patient selection based on trial 
inclusion/exclusion criteria, no significant correlation with efficacy was found with any 
of the above-mentioned factors (Appendix Tables A8 and A9). 
Moreover, other clinical factors such as performance status, and number of 
previously lines of treatment and toxicity were also compared against efficacy in a 
univariate analysis. Treatment related adverse events were consistent with 
previously reported data [4] and are summarised in Appendix Tables A10 and A11. 
As expected, patients who required >50% dose reduction and received less than 2 
cycles of regorafenib derived less benefit from the treatment (Appendix Tables A12).  
 
Discussion 
This proof of concept phase II translational research study was designed to assess 
the feasibility of combining imaging, morphological and plasma biomarkers in order to 
best stratify patients more likely to derive benefit from regorafenib in refractory 
mCRC. Our study provides the first clinical evidence that regorafenib efficacy is 
driven by its early anti-angiogenic activity. 
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It is widely accepted that DCE-MRI can assess tumour vascular function[27]; 
however, establishing common methodology remains challenging due to the 
practicalities of technical implementation across different MR platforms and the 
choice of mathematical models for data analysis. In this study, we have used DCE-
MRI acquisition and data analysis in line with international expert recommendations 
[27]. Whilst a large body of evidence supports the notion that perfusion MRI can be 
helpful in assisting dose selection and enriching patient populations more likely to 
respond in early phase clinical trials, most studies have defined an observable anti-
angiogenic drug effect based only on the limits of DCE-MRI measurement 
repeatability rather than also considering the clinical efficacy[28]. Furthermore, as 
metastases show variable degrees of necrosis and non-enhancement before 
treatment and drug induced vascular pruning also leads to marked decrease in 
enhancement within tumors, measuring only the median Ktrans value is less sensitive 
to change due to averaging of the voxel values.  For these reasons, we calculated 
the EF and the product of Ktrans from the enhancing voxels with EF (KEF), which 
better reflects proportional reduction of vascularity within tumours[24]. 
 
In this study, we have evaluated DCE-MRI in a well-defined study population, thus 
minimizing the bias that may result from patient heterogeneity. The selected DCE-
MRI parameter threshold applied for patient stratification is based on both a prior 
knowledge of the measurement repeatability of our technique [29] as well as clinically 
validated endpoints of PFS and OS. To our knowledge, this is the first prospective 
study showing that KEF, a product of Ktrans and EF, can be used as a parameter of 
DCE-MRI with high clinical specificity. The KEF measurement was able to identify 
clinically meaningful responders as early as 2 weeks into treatment with regorafenib 
with 100% specificity.  
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The major strength of this study are that it was possible to validate the findings of 
MRI detected regorafenib-induced suppression of tumour vascularisation by matched 
tissue analysis using immunostaining of the endothelial marker CD31. We 
demonstrated that patients with a significant drop in CD31 score on 2-month biopsy 
had a better PFS and OS. These findings further emphasise the fact that drug activity 
is due to its anti-proliferative properties.  
 
It is established that genetic and non-genetic mechanisms of tumour heterogeneity 
allow functional expansion of previously dormant subclones under the selective 
pressure of chemotherapy in CRC cells [30]. This provides a strong biological 
rationale for the use of regorafenib given its broad multi-kinase anti-tumour activity. 
However, the diversity of mechanisms of action of this drug makes it equally 
challenging to identify predictive biomarkers of clinical utility. Biomarker analysis of 
CORRECT trial data demonstrated that benefit from regorafenib was independent of 
the RAS pathway mutational status of the tumour, suggesting primarily an 
antiangiogenic mechanism of action, and that liquid biopsy could be reliably used to 
characterize clonal mutations[8]. We investigated if the circulating tumour genotype 
could be used as a biomarker of sustained anti-angiogenic activity to regorafenib by 
tracking known KRAS clonal mutations and performing serial plasma analysis by 
highly sensitive ddPCR methodology, at clinically relevant time points. A drop in FA 
was observed in all patients at 4 weeks suggesting a degree of initial anti-angiogenic 
activity in keeping with an initial drop in radiological parameters; however, this effect 
was sustained in only a proportion of patients at 2 months. This group of patients with 
persistent drop at 2 months demonstrated better efficacy with regorafenib suggesting 
that sustained angiogenic activity was required in order to achieve maintained benefit 
from therapy. Consistent with the findings from previous studies [25, 31], we 
demonstrated that ctDNA can be used for tumour genotyping, but beyond this we 
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proved that it can also be used to monitor efficacy from regorafenib in patients 
showing initial benefit from the therapy.  
 
Acknowledging the limitations due to small numbers of patients in our study, we 
propose that these findings should be validated in larger cohort of patients treated 
with anti-angiogenic therapies. Due to logistical barriers, it may however not be 
possible to conduct large scale trials scrupulously designed and statistically powered 
to address questions of biomarker analysis. The interpretation of our findings thus 
need to be contextualized; for example, regorafenib is currently unavailable free of 
charge to patients in the United Kingdom so the use of biomarkers described in this 
study could significantly reduce the duration of therapy in patients’ unlikely to derive 
benefit. It is conceivable that the health economic assessment might be more 
favorable with appropriate predictive biomarkers such as those we have identified.  
Whilst, the search for a positive predictive biomarker may help better application of 
precision medicine, in a more non-resource-constrained funding environment, based 
on our findings, patients could be spared from significant drug-related side effects, 
which again would have health-economic benefits.  
 
In summary, the depth of angiogenic response measured by DCE-MRI and validated 
by matched tissue IHC analysis correlates with clinical efficacy. The circulating 
tumour genotype is a potential marker of sustained anti-angiogenic response to 
regorafenib in patients with known clonal mutations.  
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Table 1: Baseline characteristics of participating patients 
 
 No. % 
   
Age, median [range] 63.7 [36.3-79.0] 
   
Gender   
Female 10 37 
Male 17 63 
   
Site of primary   
Rectal 7 26 
Left Colon 9 33 
Right Colon 11 41 
   
Histology Diagnosis   
Unknown 1 4 
Adeno (mucinous) 4 15 
Adeno (non-mucinous) 22 81 
   
Stage Diagnosis   
Stage II 5 19 
Stage III 5 19 
Stage IV 17 62 
   
Radiotherapy to 
primary 
  
Yes 4 15 
No 23 85 
   
Number of lines in 
metastatic setting 
  
1 1 4 
2 11 41 
3 9 33 
4 3 11 
5 2 7 
6 1 4 
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Figure Legends 
Figure 1: PROSPECT-R Trial design. Patients meeting all inclusion and no 
exclusion criteria were required to have pre-treatment CT, DCE-MRI, and DW-MRI 
scans; MRI scans were then repeated on day 15. All patient were also required to 
have pre-treatment mandatory core biopsy, followed by a core biopsy at 2-months if 
they had SD or PR. Patients were monitored  by CT scans every 2 months until the 
time of PD and if clinically feasible, they had biopsy of 1 or 2 progressing lesions 
from PD sites. Plasma samples were collected every 4 weeks until the time of PD. 
CT=computed tomography; ctDNA= circulating tumour DNA; DCE=dynamic contrast 
enhanced; DW= diffusion weighted; MRI=magnetic resonance imaging; 
PD=progressive disease; PR=partial response; SD= stable disease. 
 
Figure 2: Outcome according to radiological parameters in the PROSPECT-R 
Trial. Kaplan-Meier curves for progression-free survival (A) and overall survival (B) in 
patients with or without KEF drop.  
 
Figure 3: Correlation between radiological and pathological findings in the 
PROSPECT-R Trial. Panels A-C demonstrate an example of a patient with durable 
disease control of 14 months, whilst panel D-F shows example of a primary 
resistance patient (2 months). (A) Coronal DCE-MRI (central slice of a liver lesion) 
showing significant reduction in the median Ktrans [min-1] with accompanying 
histogram (whole lesion) at day 15 post-treatment. (B) Coronal CT images at 
baseline, best response (2 months) and at the end of treatment (14 months) for same 
liver lesion (left) and an abdo-pelvic mass (right). Patient achieved SD by RECIST 
v1.1. (C) Matched IHC analysis demonstrating decrease and subsequent increase in 
tumour vascularity measured by staining CD31 at 2 months and 14 months 
respectively. (D) Coronal DCE-MRI and accompanying histogram of the liver lesion 
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showing no significant reduction in the median Ktrans [min-1] at day 15 post treatment. 
(E) Coronal CT images of the liver showing progression (30% increase) of the same 
target liver lesion (yellow circle) at baseline and at progression (2 month scan). (F) 
Matched IHC analysis demonstrating no change in tumour vascularity measured by 
staining CD31 at 2 months. Two separate PD lesions were analysed to take into 
account tumour heterogeneity; however, no change in vascularity was observed in 
either of the biopsied lesion. 
CT=computed tomography; DCE=dynamic contrast enhanced; IHC-
immunohistochemistry; MRI=magnetic resonance imaging; PD=progressive disease; 
SD= stable disease. 
Figure 4: Correlation between radiological, pathological and circulating 
biomarkers in PROSPECT-R Trial. (A) Axial DCE-MRI demonstrating significant 
reduction (71%) of the median Ktrans[min -1] in the left pelvic wall recurrence, with 
accompanying histogram at day 15 post-regorafenib. (B) Three dimensional 
representation of target lesion by CT performed at baseline and at week 31 (best 
response), demonstrating reduction in lesion volume. (C) FDG-PET images 
performed at 4 months of therapy, showing residual FDG uptake, although 
significantly less when compared to a historic PET-CT performed 18 months prior to 
regorafenib therapy. (D) Axial CT images demonstrating a maintained RECIST V1.1 
PR (45%) to regorafenib for 31 weeks. Images show representative sites of disease 
including: left pelvis side wall, mediastinal lymphadenopathy, and large lung 
metastases (yellow circles). Note is made that at the time of progression, left pelvic 
side wall disease progressed (28%), while the remaining disease had maintained 
partial response demonstrating the inter-tumoural heterogeneity in resistance to 
regorafenib. (E) Matched IHC analysis demonstrating decrease and subsequent 
increase in tumour vascularity measured by staining CD31 at 2 months and 12 
months respectively. (F) Graphical representation of clonal KRAS mutation tracked 
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by ddPCR analysis of ctDNA analysis compared with CEA and total volume of target 
lesions measured RECIST v1.1 assessment. This demonstrates that an early drop 
and rise in fractional abundance (FA) of KRAS mutation that precedes changes in 
CEA, both at response and resistance to regorafenib  
CEA=Carcino-Embryonic Antigen; ctDNA=circulating tumour; CT=computed 
tomography; DCE=dynamic contrast enhanced; ddPCR=digital droplet polymerase 
chain reaction; FA=fractional abundance; FDG-PET=18-Fluoro-deoxyglucose 
positron emission tomography; IHC=immunohistochemistry; MRI=magnetic 
resonance imaging; PD=progressive disease; PR=partial response 
Figure 5: Outcome according to ctDNA drop after 2 months of treatment in the 
PROPSECT-R Trial. Kaplan-Meier curves for progression-free survival (A) and 
overall survival (B) in patients with or without ctDNA drop, (C) spider plot 
demonstrating depth and duration of response to regorafenib (evaluated by RECIST 
v1.1. criteria) according to KEF and ctDNA drop. 
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